💊Sunovion Announces Lonhala Magnair (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
– LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the
treatment of COPD in the U.S. –
Marlborough, Mass., April 3, 2018 – Sunovion Pharmaceuticals Inc. (Sunovion) today announced
that Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution (25 mcg twice daily) is now available at
pharmacies in the U.S. for the long-term, maintenance treatment of airflow obstruction in people with
chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.SUMITOMO DAINIPPON PHARMA Co., Ltd.